Stevanato Group (NYSE:STVN) Announces Earnings Results

Stevanato Group (NYSE:STVN) posted its earnings results on Tuesday. The company reported €0.16 EPS for the quarter, beating the consensus estimate of €0.15 by €0.01, Zacks reports. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%. Stevanato Group updated its FY 2026 guidance to 0.700-0.720 EPS.

Here are the key takeaways from Stevanato Group’s conference call:

• Second-quarter revenue rose 8% to €302 million, while high-value solutions grew 16% and reached 45% of total revenue. Adjusted EBITDA increased 21% to €78.7 million, with the margin expanding to 26%.
• Demand remained strong for biologics, GLP-1 therapies, and integrated drug-delivery systems. European regulatory approvals for the Alina variable-dose pen, incorporating Stevanato’s cartridge technology, could support double-digit Alina revenue growth in coming years.
• The company raised the quality of its revenue mix through growth in premium Nexa and Alba syringes and EZ-fill vials, while Fishers and Latina continued to ramp. Fishers expects customer validation of its first EZ-fill vial line soon and commercial device production later in 2026.
• Stevanato completed the divestiture of Balda C. Brewer, reducing 2026 revenue by roughly €15 million but expected to improve full-year margins. The sale generated €12.2 million in one-time expenses and contributed to lower reported operating profit and net income in the quarter.
• The Engineering segment’s revenue declined 2%, and management cautioned that elongated sales cycles and project phasing remain risks despite improving margins and new orders. Quarterly free cash flow was negative €32 million, reflecting €52 million of capital expenditures, while full-year free cash flow guidance remains only breakeven to positive €20 million.

Stevanato Group Stock Performance

STVN traded down €0.97 during trading hours on Tuesday, hitting €19.61. The company’s stock had a trading volume of 294,577 shares, compared to its average volume of 540,130. Stevanato Group has a fifty-two week low of €12.89 and a fifty-two week high of €28.00. The company has a current ratio of 1.63, a quick ratio of 1.11 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $5.94 billion, a PE ratio of 33.10, a PEG ratio of 1.77 and a beta of 0.77. The company has a 50-day simple moving average of €18.66 and a 200 day simple moving average of €16.97.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on STVN shares. Weiss Ratings upgraded Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. TD Cowen upgraded shares of Stevanato Group to a “strong-buy” rating in a research report on Wednesday, June 17th. Finally, Wolfe Research initiated coverage on shares of Stevanato Group in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Insiders Place Their Bets

In other Stevanato Group news, Director Donald E. Morel, Jr. sold 1,493 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of €17.09, for a total transaction of €25,515.37. Following the completion of the transaction, the director owned 37,424 shares in the company, valued at approximately €639,576.16. The trade was a 3.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Madhavan Balachandran sold 1,493 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of €17.09, for a total value of €25,515.37. Following the completion of the transaction, the director directly owned 69,458 shares of the company’s stock, valued at approximately €1,187,037.22. The trade was a 2.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,972 shares of company stock worth $102,061 over the last 90 days.

Hedge Funds Weigh In On Stevanato Group

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. increased its stake in Stevanato Group by 10.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,923,632 shares of the company’s stock valued at $78,944,000 after buying an additional 368,792 shares during the period. Bamco Inc. NY lifted its stake in shares of Stevanato Group by 1.4% in the 4th quarter. Bamco Inc. NY now owns 2,001,724 shares of the company’s stock worth $40,275,000 after acquiring an additional 27,965 shares during the period. Loomis Sayles & Co. L P lifted its stake in shares of Stevanato Group by 2.8% in the 4th quarter. Loomis Sayles & Co. L P now owns 788,280 shares of the company’s stock worth $15,860,000 after acquiring an additional 21,392 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Stevanato Group by 14.2% in the second quarter. Ameriprise Financial Inc. now owns 708,821 shares of the company’s stock valued at $17,316,000 after acquiring an additional 87,942 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in shares of Stevanato Group by 31.8% in the fourth quarter. MetLife Investment Management LLC now owns 650,811 shares of the company’s stock valued at $13,094,000 after acquiring an additional 156,968 shares in the last quarter.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.